Non-Current Assets
Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments
Merck & Co. Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments increased by 1.0% to $881.00M in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ3 2021
Last reportedQ1 2026
How to read this metric
An increase indicates deteriorating performance or valuation write-downs in the private equity or venture portfolio.
Detailed definition
The cumulative amount of downward fair value adjustments recognized for equity securities that lack a readily determinab...
Peer comparison
Standard for firms with significant private equity or venture capital exposure.
Metric ID:
equity_securities_no_fv_downward_adjHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $872.00M | $881.00M |
| QoQ Change | — | +1.0% |
| YoY Change | — | +1.0% |
Range$872.00M – $881.00M
Avg YoY Growth+1.0%
Median YoY Growth+1.0%
Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s equity securities without readily determinable fair value - cumulative downward adjustments?
- Merck & Co. (MRK) reported equity securities without readily determinable fair value - cumulative downward adjustments of $881.00M in Q1 2026.
- What does equity securities without readily determinable fair value - cumulative downward adjustments mean?
- Total value lost on private or hard-to-value equity investments.